All In Biotech

Drug Trial Radar · NCT03027284

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer

Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Feb 3, 2017

Primary completion

Jun 20, 2019

Study completion Mar 17, 2020

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jan 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.

Conditions

  • Advanced Cancer
  • Metastatic Cancer
  • Biliary Tract Carcinoma
  • Cholangiocarcinoma
  • Gall Bladder Carcinoma
  • Solid Tumor
  • Non-Hodgkin's Lymphoma

Interventions

  • MerestinibDrug

    Administered orally

  • CisplatinDrug

    Administered IV

  • GemcitabineDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Merestinib Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (Part A = 28 Days or Part B = 21 Days)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

    Chiba, Japan

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.